Clinical efficacy of raloxifene in postmenopausal women

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 85, Issue 1, 1999, Pages 43-46

  Agnusdei, Donato ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bone mineral density; Cardiovascular risk; Postmenopausal women; Raloxifene; SERMs

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PLACEBO; RALOXIFENE;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0033036606     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00280-2     Document Type: Conference Paper

References (25)

1. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of heart disease in women. New Engl J Med. 316:1987;1105-1110.
2. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.N., Moskowitz M.A. Hip fracture and the use of estrogen in post menopausal women: The Framingham study. New Engl J Med. 317:1987;1169-1174.
3. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report 843, Geneva: WHO, 1994.
4. Riggs B.L. Overview of osteoporosis. West J Med. 154:1991;63-77.
5. The Writing Group for the pEPI Trial. Effects of hormone replacement therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 1996;276:1389-96.
6. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-63.
7. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions trial (PEPI). J Am Med Assoc 1995;273:199-208.
8. Beresford S.A., Weiss N.S., Voigt L.F., McNight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclical progestagen therapy in postmenopsausal women. Lancet. 349:1997;458-461.
9. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med. 332:1995;1589-1593.
10. Collaborative Groups on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
11. Grodstein F., Stampfer M.J., Colditz G.A., Willet W.C., Manson J.E., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter D.J., Hennekens C.H., Speizer F.E. Postmenopausal hormone therapy and mortality. New Engl J Med. 336:1997;1769-1775.
12. Scalley E.K., Henrich J.B. An overview of estrogen replacement therapy in postmenopausal women. J Womens Health. 2(3):1993;289-294.
13. Witt D.M., Lousberg T.R. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother. 31:1997;745-755.
14. Josse R.G. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. Can Med Assoc. 155(7):1996;929-934.
15. Mitlak B.H., Cohen F.J. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 48:1997;155-163.
16. Kauffman R., Bryant H.U. Selective estrogen receptor modulators. Drug News Perspect. 8:1995;531-539.
17. Delmas P.D., Bjarnason N.H., Mitlak B.H.et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med. 337:1997;1641-1647.
18. Gunness M, Prestwood K, Lu Y, et al. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCl and Premarin in postmenopausal women. Prog Abstr 79th Annu Meet Endocrine Soc 1997;June 11-14:67.
19. Heaney R.P., Draper M.W. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab. 82(10):1997;3425-3429.
20. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S., Anderson P.W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc. 279:1998;1445-1451.
21. Jacobs D.R., Mebane I.L., Bangdiwala S.I.et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the lipid research clinics prevalence study [For the Lipid Research Clinics Program]. Am J Epidemiol. 274(10):1990;801-806.
22. Sacks F.M., Pfeffer M.A., Move L.A.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Engl J Med. 335(14):1996;1001-1009.
23. Kannel W.B., Wolf P.A., Castelli W.P., D'Agostino R.B. Fibrinogen and risk of cardiovascular disease: The Framingham Study. J Am Med Assoc. 258(9):1987;1183-1186.
24. Bjarnason N.H., Haarbo M., Byrjalsen I.et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96(6):1997;1964-1969.
25. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 83(3):1998;721-726.